← All trials
NCT03040778
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2017
- Primary completion
- Jan 1, 2019
- Completion date
- Jan 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- University of WashingtonReponsible party - principal investigator
- Oregon Health and Science UniversityCollaborator
- University of MichiganCollaborator
- New York Center for Orthognathic and Maxillofacial SurgeryCollaborator
- University of Alabama, BirminghamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.